Plain-English translation of NCT05995041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing universal CAR-T cells — immune cells that are engineered in a lab to recognize and attack acute myeloid leukemia (AML) cancer cells. Unlike traditional CAR-T cell therapy, which is customized for each patient and takes weeks to prepare, these universal cells are ready to use immediately. This could help AML patients who are very sick or whose disease is progressing quickly.
AML is a serious blood cancer that grows rapidly in the bone marrow and weakens the immune system, making it difficult to harvest and grow a patient's own immune cells in time. This medication offers a potential solution by providing pre-made, off-the-shelf cells that can be given to patients right away, without waiting for a lengthy manufacturing process.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of the universal CAR-T cells designed to target your leukemia. The research team will monitor you closely to see how well the treatment works and how your body tolerates it, including tracking how long the cells survive in your body and whether they effectively fight the cancer. The exact schedule of visits and length of follow-up will be determined by the research team based on your individual needs and response to treatment.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~30 participants
Started
June 2026
Primary completion
December 2029
Age range
6 Months – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, Ph.D
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.